Recent newsflow from Angle and the FY16 report released last week showed progress in developing and commercialising the liquid biopsy diagnostic system Parsortix. The R&D strategy is progressing, with the ovarian cancer trials recruiting first patients in the US and Europe and on track to deliver data around end-2016, while the first research use sales met our expectations and a new large client is on board. Our updated valuation of Angle is £129.6m (vs £95m previously).
01 Aug 2016
Progress with R&D and commercialisation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Progress with R&D and commercialisation
ANGLE plc (AGL:LON) | 12.5 0 0.0% | Mkt Cap: 32.6m
- Published:
01 Aug 2016 -
Author:
Dr Jonas Peciulis -
Pages:
7
Recent newsflow from Angle and the FY16 report released last week showed progress in developing and commercialising the liquid biopsy diagnostic system Parsortix. The R&D strategy is progressing, with the ovarian cancer trials recruiting first patients in the US and Europe and on track to deliver data around end-2016, while the first research use sales met our expectations and a new large client is on board. Our updated valuation of Angle is £129.6m (vs £95m previously).